FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Swedish Court Delays Judgment in Klarna’s Antitrust Case Against Google

The court's decision is crucial for Klarna's operations in the competitive market.Highlights: Swedish court delays decision on Klarna's...
FinTech

Morgan Stanley Launches Bitcoin ETF, Expanding Crypto Offerings

The investment firm broadens its reach into the cryptocurrency market.Highlights: Morgan Stanley launches a Bitcoin ETF to enhance...
FinTech

HSBC Strengthens Position with Hong Kong Stablecoin Issuer License

The banking giant aims to support digital asset initiatives in the region.Highlights: HSBC receives a stablecoin issuer license...
FinTech

US Treasury Secretary Warns Banks About Anthropic’s New AI Model

Treasury Secretary highlights risks AI poses to financial stability.Highlights: US Treasury Secretary warns banks about the risks of...